Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Executive Summary
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.
You may also be interested in...
FDA Clears iRhythm’s Afib-Detecting Wearable Running Software Co-Developed By Verily
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
CMS Proposes National Payments For Long-Term Continuous Electrocardiogram Monitoring
Analysts expect iRhythm to shift more of its long-term remote cardiac monitoring operations to its California facility to take advantage of new Medicare reimbursement rates set by the US Centers for Medicare and Medicaid Services.
Digital Health Roundup: AI Trends In Medtech; Exec Chats; FDA’s Digital Health Guru Steps Down
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights AI trends in medtech, Exec Chats with iRhythm and medical robotics authority Moshe Shoham, and key FDA updates.